Halilibrahim Ciftci received a BSc. in Chemistry from Ege University, Turkey in 2006 and an M.Sc. in Cancer Pharmacology from the Institute of Cancer Therapeutics, University of Bradford, UK in 2008. He worked at major Turkish pharmaceutical companies (i.e., Neutec, Bilim, and Deva) as an R&D senior scientist to manage all technical aspects of the product development processes. After working for four years at major pharmaceutical companies, He returned to his academic career at the School of Pharmacy at Kumamoto University, Japan in 2012 as a Japanese Government (MEXT) PhD scholar to develop anti-cancer and anti-HIV drug candidates. He received his Ph.D. in Pharmaceutical Sciences in 2016 and immediately after, he began working as a JSPS (Japanese Society for the Promotion of Science) postdoctoral fellowship at the same school. During his postdoc, he had a close collaboration with Stanford PULSE Institute for SFX-based drug development. His Research Keywords include Chemical Biology, Drug Design and Nanoparticles.